Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L)
EUR 49.06
(-1.57%)
EUR 49.06
(-1.57%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 170.33 Million EUR | -14.69% |
| 2022 | 199.66 Million EUR | 30.44% |
| 2021 | 153.07 Million EUR | 150.71% |
| 2020 | 61.05 Million EUR | 55.47% |
| 2019 | 39.27 Million EUR | 119.46% |
| 2018 | 17.89 Million EUR | 3.79% |
| 2017 | 17.24 Million EUR | -33.91% |
| 2016 | 26.08 Million EUR | 31.7% |
| 2015 | 19.8 Million EUR | -17.86% |
| 2014 | 24.11 Million EUR | 4.75% |
| 2013 | 23.02 Million EUR | 17.98% |
| 2012 | 19.51 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 29.38 Million EUR | 96.4% |
| 2024 Q1 | 14.96 Million EUR | -70.95% |
| 2023 Q1 | 47.45 Million EUR | -39.28% |
| 2023 Q2 | 19.18 Million EUR | -59.57% |
| 2023 Q3 | 52.18 Million EUR | 171.96% |
| 2023 Q4 | 51.5 Million EUR | -1.29% |
| 2023 FY | 170.33 Million EUR | -14.69% |
| 2022 Q4 | 78.16 Million EUR | 91.19% |
| 2022 Q3 | 40.88 Million EUR | 48.28% |
| 2022 FY | 199.66 Million EUR | 30.44% |
| 2022 Q2 | 27.57 Million EUR | -48.02% |
| 2022 Q1 | 53.04 Million EUR | -2.02% |
| 2021 Q2 | 27.18 Million EUR | 14.04% |
| 2021 Q4 | 54.13 Million EUR | 12.99% |
| 2021 Q3 | 47.91 Million EUR | 76.26% |
| 2021 Q1 | 23.83 Million EUR | 67.5% |
| 2021 FY | 153.07 Million EUR | 150.71% |
| 2020 Q1 | 13.91 Million EUR | 62.02% |
| 2020 Q4 | 14.23 Million EUR | -17.41% |
| 2020 Q3 | 17.23 Million EUR | 9.94% |
| 2020 FY | 61.05 Million EUR | 55.47% |
| 2020 Q2 | 15.67 Million EUR | 12.61% |
| 2019 FY | 39.27 Million EUR | 119.46% |
| 2019 Q4 | 8.59 Million EUR | -40.84% |
| 2019 Q3 | 14.52 Million EUR | 56.75% |
| 2019 Q2 | 9.26 Million EUR | 34.32% |
| 2019 Q1 | 6.89 Million EUR | 207.35% |
| 2018 Q4 | 2.24 Million EUR | -72.3% |
| 2018 Q3 | 8.1 Million EUR | 1037.78% |
| 2018 Q2 | 712 Thousand EUR | -89.59% |
| 2018 Q1 | 6.83 Million EUR | 2994.12% |
| 2018 FY | 17.89 Million EUR | 3.79% |
| 2017 Q3 | 1.26 Million EUR | -86.54% |
| 2017 Q1 | 6.37 Million EUR | 39.35% |
| 2017 FY | 17.24 Million EUR | -33.91% |
| 2017 Q4 | 221 Thousand EUR | -82.5% |
| 2017 Q2 | 9.38 Million EUR | 47.21% |
| 2016 Q2 | 8.59 Million EUR | -8.59% |
| 2016 FY | 26.08 Million EUR | 31.7% |
| 2016 Q4 | 4.57 Million EUR | 30.28% |
| 2016 Q3 | 3.51 Million EUR | -59.16% |
| 2016 Q1 | 9.4 Million EUR | 185.12% |
| 2015 FY | 19.8 Million EUR | -17.86% |
| 2015 Q4 | 3.29 Million EUR | 12.21% |
| 2015 Q3 | 2.94 Million EUR | -58.7% |
| 2015 Q2 | 7.11 Million EUR | 10.35% |
| 2015 Q1 | 6.45 Million EUR | 51.68% |
| 2014 Q4 | 4.25 Million EUR | -13.35% |
| 2014 FY | 24.11 Million EUR | 4.75% |
| 2014 Q1 | 5.93 Million EUR | 36.45% |
| 2014 Q2 | 9.02 Million EUR | 52.19% |
| 2014 Q3 | 4.9 Million EUR | -45.62% |
| 2013 Q2 | 8.49 Million EUR | 59.09% |
| 2013 Q4 | 4.34 Million EUR | -10.32% |
| 2013 FY | 23.02 Million EUR | 17.98% |
| 2013 Q3 | 4.84 Million EUR | -42.93% |
| 2013 Q1 | 5.33 Million EUR | 85.22% |
| 2012 Q4 | 2.88 Million EUR | 0.0% |
| 2012 FY | 19.51 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Boiron SA | 35.82 Million EUR | -375.438% |
| Vetoquinol SA | 55.56 Million EUR | -206.578% |
| Valneva SE | -101.42 Million EUR | 267.935% |
| AB Science S.A. | -10.04 Million EUR | 1795.213% |
| Nanobiotix S.A. | -39.7 Million EUR | 529.055% |
| PHAXIAM Therapeutics S.A. | -23.48 Million EUR | 825.2% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 700.999% |
| BioSenic S.A. | -28.77 Million EUR | 691.893% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 215.294% |
| Formycon AG | 75.79 Million EUR | -124.731% |